Practice-entering research
DYNAMIC — ctDNA-guided adjuvant chemotherapy (stage II colon)
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colon Cancer (DYNAMIC)
- Phase
- Phase II
- Recruitment
- Completed
- Results maturity
- Primary analysis
- Publication
- Peer-reviewed
- Regulatory approval
- No regulatory approval
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-31
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? Blood tumor DNA after surgery is being used to help decide whether chemotherapy is truly needed.
Why promising? Strategy to cut unnecessary adjuvant chemo while preserving 2-year recurrence-free survival (non-inferiority) using ctDNA.
What is not proven? All stages/countries; equivalence of every ctDNA assay; universal stage III protocol.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
NEJM 2022: adjuvant chemo 15% vs 28%; 2y RFS 93.5% vs 92.4% (non-inferiority). ANZCTR-registered (not NCT). CIRCULATE / DYNAMIC-III are separate.
Cancer / population: Colon — Evre II kolon kanseri
Intervention: ctDNA pozitifse adjuvan KT; negatifse gözlem
Primary endpoint: 2 yıllık nükssüz sağkalım (RFS; non-inferiority) ve adjuvan KT kullanım oranı
Source-verified summary: 2y RFS %93,5 vs %92,4 (non-inferiority); adjuvan KT %15 vs %28 — Kolon Landmark ile hizalı.
Limitations: Assay ve sağlık sistemi bağımlı; evre III ayrı programlar.
Landmark Atlas links
Cross-links are informational only; this module does not award or change gold stars.